Effects of power training in older patients with multiple sclerosis on neurodegeneration, neuromuscular function, and physical function. A study protocol for the “power training in older multiple sclerosis patients (PoTOMS) randomized control trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 0,99 MB, PDF-dokument

  • Tobias Gaemelke
  • Christoffer Laustsen
  • Peter Feys
  • Lars Folkestad
  • Marianne Skovsager Andersen
  • Jørgensen, Niklas Rye
  • Marie Louise Jørgensen
  • Sune Nørhøj Jespersen
  • Steffen Ringgaard
  • Simon F. Eskildsen
  • Ulrik Dalgas
  • Lars G. Hvid
Introduction
Approximately one-third of all persons with multiple sclerosis (pwMS) are older, i.e., having an age ≥60 years. Whilst ageing and MS separately elicit deteriorating effects on brain morphology, neuromuscular function, and physical function, the combination of ageing and MS may pose a particular challenge. To counteract such detrimental changes, power training (i.e., a type of resistance exercise focusing on moderate-to-high loading at maximal intended movement velocity) presents itself as a viable and highly effective solution. Power training is known to positively impact physical function, neuromuscular function, as well as brain morphology. Existing evidence is promising but limited to young and middle-aged pwMS, with the effects of power training remaining to be elucidated in older pwMS.

Methods
The presented ‘Power Training in Older MS patients (PoTOMS)’ trial is a national, multi-center, parallel-group, randomized controlled trial. The trial compares 24 weeks of usual care(n = 30) to 24 weeks of usual care and power training (n = 30). The primary outcome is whole brain atrophy rate. The secondary outcomes include changes in brain micro and macro structures, neuromuscular function, physical function, cognitive function, bone health, and patient-reported outcomes.

Ethics and dissemination
The presented study is approved by The Regional Ethics Committee (reference number 1-10-72-222-20) and registered at the Danish Data Protection Agency (reference number 2016-051-000001). All study findings will be published in scientific peer-reviewed journals and presented at relevant scientific conferences independent of the results. The www.clinicaltrials.gov identifier is NCT04762342.
OriginalsprogEngelsk
Artikelnummer101279
TidsskriftContemporary Clinical Trials Communications
Vol/bind38
Antal sider10
ISSN2451-8654
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The study is financed by Aarhus University, Faculty of Health (Vennelyst Boulevard 4, 8000 Aarhus C, DK, health@au.dk ) and by the following external foundations: 'Trygfonden', The Danish MS Society 'Scleroseforeningen', ’Jascha fonden’, ’Helsefonden’, and The Danish Osteoporosis Society ’Osteoporose foreningen’.

Publisher Copyright:
© 2024 The Authors

ID: 385691832